Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics

References

• Lebergeber B, Egger M, Opravil M, etal. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet353, 863–868 (1999).
   Google Scholar
• Wit FWNM, Van Leeuwen R, Weverling GJ, et al Outcomes and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type-1-infected persons. j Infect. Dis. 179,790–798 (1999).
   Web of Science ®Google Scholar
• Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 131,81–87 (1999).
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, etal Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133,21–30 (2000).
   PubMed Web of Science ®Google Scholar
• Little SJ, Holte S, Routy JP, etal Antiretroviral-drug resistance among patients recently infected with HIV N Engl. I Med. 347,385–394 (2002).
   PubMed Web of Science ®Google Scholar
• Molla A, Korneyeva M, Gao Q, et al Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. 124,1039–1050 (1996).
   Google Scholar
• Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res. Hum. Retrovirus 18,825–834 (2002).
   PubMed Web of Science ®Google Scholar
• Back D, Gatti G, Fletcher C, etal Therapeutic drug monitoring in HIV infection: current status and future directions. A/DS16\(Suppl. 1), S5—S37 (2002).
   Google Scholar
• Piscitelli SC. The role of therapeutic drfug monitoring in the management of HIV-infected patients. CU17: Infect. Dis. Rep. 4, 353–358 (2002).
   Google Scholar
• Burger D, Hugen P, Droste J, etal Therapeutic drug monitoring (TDM) of nelfinavir (NFV) and indinavir (IDV) in treatment-naive patients improves therapeutic outcome after 1 year: results from ATHENA. The 1st IAS Conference on HIV Pathogenesis and Tmatrnent, Buenos Aires, Argentina (2001) (Abstract 30).
   Google Scholar
• Fletcher CV, Anderson PL, Kakuda TN, etal Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS16,551-560 (2002).
   Google Scholar
• Dieleman JP, van Rossum AM, Stricker BC, etal Persistant leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. AID532, 135–142 (2003).
   Google Scholar
• Marzolini C, Telenti A, Decosterd LA, etal. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS15,71-75 (2001).
   Google Scholar
• Clevenbergh P, Garaffo R, Durant J, etal PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic drug monitoring of protease inhibitors: 12 week results. AIDS16, 2311–2315 (2002).
   Google Scholar
• Heeswijk van RR Critical issues in therapeutic drug monitoring of antiretroviral drugs. Ther. Drug-Monit. 24, 323–331 (2002).
   PubMed Web of Science ®Google Scholar
• Sadler BM, Gillotin C, Lou C, etal Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob. Agents Chemother. 45,30–37 (2001).
   PubMed Web of Science ®Google Scholar
• Drusano GL, Bilello JA, Preston SL, etal. Hollow-fiber unit evaluation of a new human immunodeficiency virus Type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacokinetic variable. j Infect. Dis. 183,1126–1129 (2001).
   Web of Science ®Google Scholar
• Schulman N, Zolopa A, Havlir D, etal Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob. Agents Chemother. 46, 3907–3916 (2002).
   PubMed Web of Science ®Google Scholar
• Fletcher CV, Anderson PL, Hoody D, etal A composite concentration index to assess antiretroviral regimen potency. 10th Conference on Retrovimses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 150).
   Google Scholar
• Aarnoutse RE, Verweij-van Wissen CPWGM, Underberg WJM, etal High-performance liquid chromatography of HIV protease inhibitors in human biological matrices. j Chromatograph B. 764,363–384 (2001).
   PubMed Web of Science ®Google Scholar
• Aarnoutse RE, Verweij-van Wissen CP, Van Ewijk-Beneken Kolmer EW, etal. International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrob. Agents Chemother. 46, 884–886 (2002).
   PubMed Web of Science ®Google Scholar
• Hsu A, Isaacson J, Brun S, etal Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47,350–359 (2003).
   PubMed Web of Science ®Google Scholar
• Acosta EP, King JR. Methods of integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus. Gun. Infect. Dis. 36,373–377 (2003).
   PubMed Web of Science ®Google Scholar
• Casado JL, Moreno A, Sabido R, etal Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response. AIDS17, 262–264 (2003).
   Google Scholar
• Ellner PD, Neu HC. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. /V/A 246,1575–1578 (1981).
   Google Scholar
• Piliero PJ. The utility of inhibitory quotients in determining the relative potency of protease inhibitors. AIDS16, 799–800 (2002).
   Google Scholar
• Montaner J, Hill A, Acosta E. Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios. Lancet 357, 1438–1440 (2001).
   PubMed Web of Science ®Google Scholar
• Marcelin AG, Lamotte C, Delaugerre C, etal Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in hum immunodeficiency virus Type 1 protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 47,594–600 (2003).
   PubMed Web of Science ®Google Scholar
• Broder S, Subramanian G, Venter JC. The Human Genome. In: Pharmacogenomics: The Search for Individualized Therapies. Licinio J, Wong ML (Eds). Wiley-VCH Verlag GmbH, Weinheim, Germany (2002).
   Google Scholar
• Telenti A, Aubert V, Spertini F, etal Individualizing HIV treatment — pharmacogenetics and immunogenetics. Lancet 359,722–723 (2002).
   PubMed Web of Science ®Google Scholar
• Smith MW, Dean M, Carrington M, etal. Contrasting genetic influence of CCR2 and CCR5variants on HIV-1 infection and disease progression. Science 277,959–965 (1997).
   PubMed Web of Science ®Google Scholar
• Wit FW, van Rij RP, Weverling GJ, etal. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 641 polymorphism do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus Type 1-infected patients. I Infect. Dis. 186,1726–1732 (2002).
   Web of Science ®Google Scholar
• Carrington M, Nelson G, O'Brien SJ.Considering genetic profiles in functional studies of immune responsiveness to HIV-1. Immunology Lett. 79,131–140 (2001).
   PubMed Web of Science ®Google Scholar
• Miserez AR, Muller PY, Barella L, et al A single-nucleotide polymorphism in the sterol-regulatory element-binding protein lc gene is predictive of HIV-regulated hyperlipoproteinaemia. AIDS15, 2045 2049 (2001).
   Google Scholar
• Mahler B, Alfiveric A, Vilar FJ, etal TNF-a promotor region gene polymorphism in HIV-positive patients with lipodystrophy. AIDS16, 2013-2018 (2002).
   Google Scholar
• Nolan D, Moore C, Castley A, etal. Tumor necrosis factor gene-238G/A promotor polymorphism associated with a more rapid onset of lipodystrphy. AIDS 17, 121–123 (2003).
   Google Scholar
• Mallal S, Nolan D, Witt C, etal. Association between presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet359, 727–732 (2002).
   Google Scholar
• Hetherington S, Hughes AR, Mosteller M, etal Genetic variations in HLA-B region and hypersenstivity reactions to abacavir. Lancet359, 1121–1122 (2002).
   Google Scholar
• Fellay J, Marzolini C, Meaden ER, etal Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multi-drug resistance transporter 1: a pharmacogenetics study. Lancet 359,30–36 (2002).
   PubMed Web of Science ®Google Scholar
• Brumme ZL, Dong WWY, Chan KJ, etal Influence of polymorphisms within CX3CR1 and MDR1 genes on initial antiretroviral therapy response. AIDS17, 201–208 (2003).
   Google Scholar
• Meyer UA. Pharmacogenetics and adverse drug reactions. Adv. Drug-React. 356, 1667–1671 (2000).
   Google Scholar
• Lennard MS, Silas JH, Freestone S, etal Oxidation phenotype — a major determinant of metoprolol metabolism and response. N Engl. Med 307,1558–1560 (1982).
   PubMed Web of Science ®Google Scholar
• Wuttke H, Rau T, Heide R, etal Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol associated adverse effects. Clin. Pharmacol Ther. 72,429–437 (2002).
   PubMed Web of Science ®Google Scholar
• Fellay J, Marzolini C, Greub G, etal. Predictive power of P-glycoprotein and CYP2D6 polymorphisms for plasma levels of antiretroviral agents. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA (2001) (Abstract 260).
   Google Scholar
• Huisman MT, Smit JVV, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS14, 237–242 (2000).
   Google Scholar
• Hoffmeyer S, Burk O, von Richetr O, etal Functional polymorphisms of the human multi-drug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Nati Acad. Sci. USA 97,3473–3478 (2000).
   PubMed Web of Science ®Google Scholar
• Schwab M, Eichelbaum M, Fromm ME. Genetic polymorphism of the human MDR1 drug transporter. Ann. Rev Pharmacol Toxicol 43,285–307 (2003).
   PubMed Web of Science ®Google Scholar
• Johne A, Kopke K, Gerloff T, etal Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Phatmacol Ther. 72, 584–594 (2002).
   PubMed Web of Science ®Google Scholar
• Singh K, Saitoh A, Powell C, etal Allelic variants of MDR1 alter pharmacokinetics of nelfinavir resulting in higher drug levels and more rapid decline in plasma in HIV-1 RNA in children. 1011 Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 100).
   Google Scholar
• Maher B, Hoggard PG, Chandler B, etal. The effect of ABCB1 (MDR1) polymorphism on the plasma and intracellular pharmacokinetics of indinavir and glucose handling in healthy volunteers. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 524a).
   Google Scholar
• Verstuyft C, Marcellin F, Morgand-Joubert L, et al. Impact of MDR1 (C3435T) genetic polymorphism in patients naive treated with HAART including indinavir. 1C1h Confemnce on Retroviruses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 522).
   Google Scholar
• Nasi M, Borghi V, Pinti M, etal MDR-1 genetic polymorphism does not influence the response to antiretroviral therapy with protease inhibitors in drug-naive patients with HIV infection. 10th Conference on Retnwiruses and Opportunistic Infections, Boston, MA, USA, (2003 (Abstract 523).
   Google Scholar
• Peterson C, Pun E, Myrand S, etal. Allelic variants of MDR1, CYP2C19 and CYP3A5: distribution and associations in patients receiving nelfinavir or efavirenz-containing HAART. 10th Conference on Retnwiruses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 575).
   Google Scholar